BioAffinity Technologies (BIAF) announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. The company stated this patent strengthens the international protection of its diagnostic platform that powers its flagship test, CyPath Lung. The Canadian patent, titled “System and Method for Determining Lung Health,” protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Technologies Secures Chinese Patent for Lung Cancer Detection
- BioAffinity receives China patent for noninvasive lung cancer diagnostic
- BioAffinity Technologies gets China patent for siRNA-based cancer therapy
- bioAffinity Receives Nasdaq Non-Compliance Notice
- BioAffinity gets U.S. patent for novel broad spectrum cancer therapies